Thank You!
We will contact you shortly. In the meantime, check out our social media and latest publications
The latest from Median
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
Median Technologies reports 2025 Q1 key financial indicators and provides an update on Q1 key operational achievements.
RELIVE pivotal study final results show that Median’s eyonis™ LCS SaMD met all key endpoints, demonstrating statistically significant performance, superior to state of the art, as well as device safety and efficacy. The results support the intended use for which eyonis™ LCS was developed, which was shared with the EU Notified Body and discussed with the FDA during the Q-submission phase.
Median will be exhibiting at the ESMO Congress on October 17 – 21 in Berlin. Happy to see you there at Messe Berlin!
Median will be exhibiting at the 2025 ASCO Annual Meeting, which will take place from May 30 to June 3 in Chicago, IL. Meet us at McCormick Place South, Hall A, Booth #11046 to learn more about our breakthrough imaging solutions and services for oncology clinical trials.
eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions
Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.
Median will be exhibiting at the American Thoracic Society (ATS) International Conference in San Francisco, from May 18-21, 2025. Meet us at Moscone Center, Hall A B C, Booth #1662 to explore our eyonis™ LCS: our cutting-edge AI/ML-based CADe/CADx SaMD for Lung cancer screening.
Conferences
May 30 to June 3, 2025ASCO 2025
Du 30 mai au 3 Juin, Median participe à la réunion annuelle de l’ASCO qui se tiendra à Chicago. Nous serons heureux de vous retrouver sur notre stand #11046 McCormick Place South, Exhibit Hall A.
